Amivantamab Dosage
Medically reviewed by Drugs.com. Last updated on Jul 29, 2024.
Applies to the following strengths: vmjw 50 mg/mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Non-Small Cell Lung Cancer
Weeks 1 to 4:
- Less than 80 kg: 1050 mg IV once a week for 4 doses
- At least 80 kg: 1400 mg IV once a week for 4 doses
Week 5 onwards:
- Less than 80 kg: 1050 mg IV every 2 weeks
- At least 80 kg: 1400 mg IV every 2 weeks
Duration of therapy: Until disease progression or unacceptable toxicity.
Infusion Rates for 1050 mg Dose:
- Week 1 (split dose infusion):
- Day 1 (350 mg dose):
- Initial rate: 50 mL/hour
- Subsequent rate: 75 mL/hour
- Day 2 (700 mg dose):
- Initial rate: 50 mL/hour
- Subsequent rate: 75 mL/hour
- Week 2 (1050 mg dose): 85 mL/hour
- Subsequent weeks (1050 mg dose): 125 mL/hour
Infusion Rates for 1400 mg Dose:
- Week 1 (split dose infusion):
- Day 1 (350 mg dose):
- Initial rate: 50 mL/hour
- Subsequent rate: 75 mL/hour
- Day 2 (1050 mg dose):
- Initial rate: 35 mL/hour
- Subsequent rate: 50 mL/hour
- Week 2 (1400 mg dose): 65 mL/hour
- Week 3 (1400 mg dose): 85 mL/hour
- Subsequent weeks (1400 mg dose): 125 mL/hour
Comments:
- The dose should be based on baseline body weight; dose adjustments are not needed for subsequent body weight changes.
- The initial dose should be administered as a split infusion in Week 1, on Day 1 and Day 2.
- Before the initial infusion on Week 1 (Days 1 and 2), premedication should be administered to reduce the risk of infusion-related reactions.
- An antihistamine and antipyretic should be administered before all infusions.
- A glucocorticoid is required for Week 1 (Days 1 and 2) doses only and should be used as needed for subsequent infusions.
- The initial infusion rate may be increased to the subsequent infusion rate after 2 hours without an infusion-related reaction.
Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by US FDA-approved test, whose disease has progressed on/after platinum-based chemotherapy
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
Dose reductions for adverse reactions:
- Less than 80 kg:
- First dose reduction: 700 mg
- Second dose reduction: 350 mg
- Third dose modification: This drug should be discontinued.
- At least 80 kg:
- First dose reduction: 1050 mg
- Second dose reduction: 700 mg
- Third dose modification: This drug should be discontinued.
Dermatologic Adverse Reactions (including acneiform dermatitis, pruritus, dry skin):
- Grade 2: Supportive care management should be started. Reactions should be reassessed after 2 weeks; if rash does not improve, dose reduction should be considered.
- Grade 3: This drug should be withheld, and supportive care management should be started. Upon recovery to Grade 2 or less, this drug should resume at a reduced dose; if no improvement within 2 weeks, this drug should be permanently discontinued.
- Grade 4 and severe bullous, blistering, or exfoliating skin conditions (including toxic epidermal necrolysis): This drug should be permanently discontinued.
Infusion-Related Reactions:
- Grade 1 to 2: The infusion should be interrupted if infusion-related reaction is suspected; the patient should be monitored until reaction symptoms resolve. The infusion should resume at 50% of the infusion rate at which the reaction occurred; if there are no additional symptoms after 30 minutes, the infusion rate may be increased according to the recommended infusion rate. A corticosteroid should be included with premedications for the next dose.
- Grade 3: The infusion should be interrupted, and supportive care agents should be administered; the patient should be monitored until reaction symptoms resolve. The infusion should resume at 50% of the infusion rate at which the reaction occurred; if there are no additional symptoms after 30 minutes, the infusion rate may be increased according to the recommended infusion rate. A corticosteroid should be included with premedications for the next dose.
- Recurrent Grade 3 or Grade 4: This drug should be permanently discontinued.
Interstitial Lung Disease (ILD)/Pneumonitis:
Any Grade:
- Suspected ILD/pneumonitis: This drug should be withheld.
- Confirmed ILD/pneumonitis: This drug should be permanently discontinued.
Other Adverse Reactions:
- Grade 3: This drug should be withheld until recovery to Grade 1 or less or baseline. If recovery occurs within 7 days, this drug should resume at the same dose; if recovery occurs after 7 days (but within 4 weeks), this drug should resume at a reduced dose. If recovery does not occur within 4 weeks, this drug should be permanently discontinued.
- Grade 4: This drug should be withheld until recovery to Grade 1 or less or baseline. If recovery occurs within 4 weeks, this drug should resume at a reduced dose; this drug should be permanently discontinued if recovery does not occur within 4 weeks or for recurrent Grade 4 reactions.
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Select patients for treatment based on the presence of EGFR exon 20 insertion mutations; for information on US FDA-approved tests: http://www.fda.gov/CompanionDiagnostics.
- Administer premedication to reduce the risk of infusion-related reactions; premedications include:
- Antihistamine (diphenhydramine [25 to 50 mg] or equivalent): Administer 15 to 30 minutes (IV) or 30 to 60 minutes (oral) before administration of this drug; required at all doses.
- Antipyretic (acetaminophen [650 to 1000 mg]): Administer 15 to 30 minutes (IV) or 30 to 60 minutes (oral) before administration of this drug; required at all doses.
- Glucocorticoid (dexamethasone [10 mg] or methylprednisolone [40 mg] or equivalent): Administer IV 45 to 60 minutes before administration of this drug; required at initial dose (Week 1, Days 1 and 2) but optional for subsequent doses.
- Administer the diluted solution by IV infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, nonpyrogenic, low protein-binding polyethersulfone (PES) filter (pore size: 0.2 micrometer) primed with diluent only.
- Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), polyvinylchloride (PVC), polypropylene (PP), or polyethylene (PE).
- Due to the high incidence of infusion-related reactions during initial therapy, infuse this drug via a peripheral line for Weeks 1 and 2; infusions may be administered via central line for subsequent weeks.
- Do not infuse this drug concomitantly in the same IV line with other agents.
- To improve biological medicinal product traceability, the name and batch number of the administered product should be clearly recorded.
Storage requirements:
- Unopened vials: Store in a refrigerator at 2C to 8C (36F to 46F) in original carton to protect from light; do not freeze.
- Diluted solutions: Administer within 10 hours (including infusion time) at room temperature 15C to 25C (59F to 77F).
Reconstitution/preparation techniques:
- This drug should be diluted and prepared for IV infusion before administration; infusion bags must be made of PVC, PP, PE, or polyolefin blend (PP+PE).
- The initial infusion should be prepared as close to administration time as possible to allow for a possibly extended infusion time in case of an infusion-related reaction.
- The manufacturer product information should be consulted.
IV compatibility:
- Compatible: 5% dextrose solution, 0.9% sodium chloride solution
General:
- This indication was approved under accelerated approval based on overall response rate and duration of response; continued approval may depend on verification and description of clinical benefit in confirmatory trials.
Monitoring:
- General: For any signs/symptoms of infusion reactions (during infusion)
- Respiratory: For new/worsening symptoms indicative of ILD/pneumonitis (during therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Patient Information).
- Notify health care provider immediately if any signs/symptoms of infusion-related reactions occur.
- Contact health care provider immediately for new/worsening respiratory symptoms.
- Limit direct sun exposure during therapy and for 2 months after the last dose; use broad-spectrum ultraviolet A (UVA)/ultraviolet B (UVB) sunscreen and wear protective clothing during therapy. Apply alcohol-free emollient cream to dry skin.
- Contact ophthalmologist if eye symptoms develop; contact lenses should be discontinued until symptoms are evaluated.
- Contact health care provider for signs/symptoms of paronychia.
- Patients of childbearing potential: Use effective contraception during therapy and for 3 months after the last dose; notify health care provider of a known/suspected pregnancy.
- Do not breastfeed during therapy and for 3 months after the last dose.
Frequently asked questions
More about amivantamab
- Check interactions
- Compare alternatives
- Reviews (4)
- Side effects
- During pregnancy
- Drug class: miscellaneous bispecific antibodies
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.